222 related articles for article (PubMed ID: 36913304)
1. Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (
Bou Zerdan M; Ashok Kumar P; Haroun E; Srivastava N; Ross J; Sivapiragasam A
Oncotarget; 2023 Mar; 14():178-187. PubMed ID: 36913304
[TBL] [Abstract][Full Text] [Related]
2. HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study.
Ghelani GH; Zerdan MB; Jacob J; Spiess PE; Li R; Necchi A; Grivas P; Kamat A; Danziger N; Lin D; Huang R; Decker B; Sokol ES; Cheng L; Pavlick D; Ross JS; Bratslavsky G; Basnet A
Urol Oncol; 2023 Dec; 41(12):486.e15-486.e23. PubMed ID: 37821306
[TBL] [Abstract][Full Text] [Related]
3. Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency.
Ashok Kumar P; Graziano SL; Danziger N; Pavlick D; Severson EA; Ramkissoon SH; Huang RSP; Decker B; Ross JS
Cancer Med; 2023 Jan; 12(2):1157-1166. PubMed ID: 35747993
[TBL] [Abstract][Full Text] [Related]
4. Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers.
Ngoi NYL; Tang TY; Gaspar CF; Pavlick DC; Buchold GM; Scholefield EL; Parimi V; Huang RSP; Janovitz T; Danziger N; Levy MA; Pant S; De Armas AD; Kumpula D; Ross JS; Javle M; Rodon Ahnert J
Oncologist; 2024 Jun; 29(6):493-503. PubMed ID: 38330461
[TBL] [Abstract][Full Text] [Related]
5. Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers.
Karikari CA; Mullendore M; Eshleman JR; Argani P; Leoni LM; Chattopadhyay S; Hidalgo M; Maitra A
Mol Cancer Ther; 2005 Dec; 4(12):1860-6. PubMed ID: 16373701
[TBL] [Abstract][Full Text] [Related]
6. Novel synthetic lethality drug target in urothelial bladder cancer based on MTAP genomic loss.
Basin MF; Bratslavsky G; Nahhas N; Basnet A; Goldberg H; Necchi A; Sokol ES; Ramkissoon SH; Huang RSP; Ross JS; Jacob JM
Urol Oncol; 2023 Feb; 41(2):109.e15-109.e22. PubMed ID: 36443178
[TBL] [Abstract][Full Text] [Related]
7. Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications.
Powell EL; Leoni LM; Canto MI; Forastiere AA; Iocobuzio-Donahue CA; Wang JS; Maitra A; Montgomery E
Am J Surg Pathol; 2005 Nov; 29(11):1497-504. PubMed ID: 16224217
[TBL] [Abstract][Full Text] [Related]
8. Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.
Sivapiragasam A; Ashok Kumar P; Sokol ES; Albacker LA; Killian JK; Ramkissoon SH; Huang RSP; Severson EA; Brown CA; Danziger N; McGregor K; Ross JS
Cancer Med; 2021 Jan; 10(1):53-61. PubMed ID: 33314633
[TBL] [Abstract][Full Text] [Related]
9. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.
Kryukov GV; Wilson FH; Ruth JR; Paulk J; Tsherniak A; Marlow SE; Vazquez F; Weir BA; Fitzgerald ME; Tanaka M; Bielski CM; Scott JM; Dennis C; Cowley GS; Boehm JS; Root DE; Golub TR; Clish CB; Bradner JE; Hahn WC; Garraway LA
Science; 2016 Mar; 351(6278):1214-8. PubMed ID: 26912360
[TBL] [Abstract][Full Text] [Related]
10. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.
Mavrakis KJ; McDonald ER; Schlabach MR; Billy E; Hoffman GR; deWeck A; Ruddy DA; Venkatesan K; Yu J; McAllister G; Stump M; deBeaumont R; Ho S; Yue Y; Liu Y; Yan-Neale Y; Yang G; Lin F; Yin H; Gao H; Kipp DR; Zhao S; McNamara JT; Sprague ER; Zheng B; Lin Y; Cho YS; Gu J; Crawford K; Ciccone D; Vitari AC; Lai A; Capka V; Hurov K; Porter JA; Tallarico J; Mickanin C; Lees E; Pagliarini R; Keen N; Schmelzle T; Hofmann F; Stegmeier F; Sellers WR
Science; 2016 Mar; 351(6278):1208-13. PubMed ID: 26912361
[TBL] [Abstract][Full Text] [Related]
11. Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines.
de Oliveira SF; Ganzinelli M; Chilà R; Serino L; Maciel ME; Urban Cde A; de Lima RS; Cavalli IJ; Generali D; Broggini M; Damia G; Ribeiro EM
PLoS One; 2016; 11(1):e0145647. PubMed ID: 26751376
[TBL] [Abstract][Full Text] [Related]
12. Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine.
Barekatain Y; Ackroyd JJ; Yan VC; Khadka S; Wang L; Chen KC; Poral AH; Tran T; Georgiou DK; Arthur K; Lin YH; Satani N; Ballato ES; Behr EI; deCarvalho AC; Verhaak RGW; de Groot J; Huse JT; Asara JM; Kalluri R; Muller FL
Nat Commun; 2021 Jul; 12(1):4228. PubMed ID: 34244484
[TBL] [Abstract][Full Text] [Related]
13. Expression of methylthioadenosine phosphorylase cDNA in p16-, MTAP- malignant cells: restoration of methylthioadenosine phosphorylase-dependent salvage pathways and alterations of sensitivity to inhibitors of purine de novo synthesis.
Chen ZH; Olopade OI; Savarese TM
Mol Pharmacol; 1997 Nov; 52(5):903-11. PubMed ID: 9351982
[TBL] [Abstract][Full Text] [Related]
14. MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis.
Marjon K; Cameron MJ; Quang P; Clasquin MF; Mandley E; Kunii K; McVay M; Choe S; Kernytsky A; Gross S; Konteatis Z; Murtie J; Blake ML; Travins J; Dorsch M; Biller SA; Marks KM
Cell Rep; 2016 Apr; 15(3):574-587. PubMed ID: 27068473
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of methylthioadenosin phosphorylase by homozygous deletion in gastric carcinoma.
Kim J; Kim MA; Min SY; Jee CD; Lee HE; Kim WH
Genes Chromosomes Cancer; 2011 Jun; 50(6):421-33. PubMed ID: 21412930
[TBL] [Abstract][Full Text] [Related]
16. Loss of 5'-Methylthioadenosine Phosphorylase (MTAP) is Frequent in High-Grade Gliomas; Nevertheless, it is Not Associated with Higher Tumor Aggressiveness.
Menezes WP; Silva VAO; Gomes INF; Rosa MN; Spina MLC; Carloni AC; Alves ALV; Melendez M; Almeida GC; Silva LSD; Clara C; da Cunha IW; Hajj GNM; Jones C; Bidinotto LT; Reis RM
Cells; 2020 Feb; 9(2):. PubMed ID: 32093414
[TBL] [Abstract][Full Text] [Related]
17. Methylthioadenosine phosphorylase cDNA transfection alters sensitivity to depletion of purine and methionine in A549 lung cancer cells.
Hori H; Tran P; Carrera CJ; Hori Y; Rosenbach MD; Carson DA; Nobori T
Cancer Res; 1996 Dec; 56(24):5653-8. PubMed ID: 8971171
[TBL] [Abstract][Full Text] [Related]
18. Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance.
Gjuka D; Adib E; Garrison K; Chen J; Zhang Y; Li W; Boutz D; Lamb C; Tanno Y; Nassar A; El Zarif T; Kale N; Rakaee M; Mouhieddine TH; Alaiwi SA; Gusev A; Rogers T; Gao J; Georgiou G; Kwiatkowski DJ; Stone E
Cancer Cell; 2023 Oct; 41(10):1774-1787.e9. PubMed ID: 37774699
[TBL] [Abstract][Full Text] [Related]
19. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
Illei PB; Rusch VW; Zakowski MF; Ladanyi M
Clin Cancer Res; 2003 Jun; 9(6):2108-13. PubMed ID: 12796375
[TBL] [Abstract][Full Text] [Related]
20. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
